Hanson









Worked for them for awhile, sold ZB stock at 170, got the fack out.

Middle to upper management couldn't decide to buy or develop new products and therefore got neither. Salesforce that I talked to don't like leadership. Morons that BH brought in messed up so many M&A deals that half my team left. Feel sorry for the backfill, if that gets approved.
 




BH can't cut a M&A deal to save his life, costs are increasing and he can't raise prices, his corporate debt costs will double this year, his right hand hombre is certifiable, and the plebes don't see any vision or strategy (let's go!). Time for another vacation!
 




Man I miss the old days when these chats were fun (people sleeping with bosses, rumors of getting sold, trivia about VPs..). Now is just the two of you talking shit about Bryan Hanson. Do you realize that the field doesnt care about who the CEO is? Just you do given your past with him?
 




Man I miss the old days when these chats were fun (people sleeping with bosses, rumors of getting sold, trivia about VPs..). Now is just the two of you talking shit about Bryan Hanson. Do you realize that the field doesnt care about who the CEO is? Just you do given your past with him?
Wrong. Crazy Karen Hanson still trying to give her input into Zimmers business. CEO and Fam making Zimmer look bad for years now. Incredible.
 








Meh. The whole market and medtech sector is down. Nothing extraordinary and ZBH shareholders are along for the ride. But better hope that IT can hold the line on pricing as cost inflation is going to hurt.
 
























Can you imagine the ladies that utilize amandahanson.com

“ooo Amanda, my husband only brought in 14 mil from the hedge fund this year so I am depressed. He promised that property in London and now we have to wait until next year”
“Dear, just keep your powerful head up and continue down your path towards the ultimate goal of strength which you have. Remember, it’s his money that will be your tool to lead you to what you are meant to be”. Please Venmo me the $8,000 for this session and will see you at the cocktail party this evening.
 




















The research analysts see right through this nonsense and focus on metrics that matter:

Matson at Needham & Co. downgraded ZBH shares because he thought inflationary pressure on Zimmer Biomet’s gross margin will carry into 2023, resulting in slow EPS growth until at least 2024. “In addition, ZBH has been losing share in its hip and knee business, and we’re not sure what will reverse this trend.”